Info

The Psychedelic Podcast

The Psychedelic Podcast connects you to the leaders and pioneers of the psychedelic renaissance. From deep healing to creativity, leadership to spirituality, business, health, human performance, relationships, sexuality, and even culture itself—every aspect of our world is being transformed by psychedelic medicines. Get an inspired, informed, balanced look into how these powerful medicines are already being safely and responsibly used to catalyze both personal and collective transformation. Whether you’re just curious or a seasoned psychonaut, or somewhere in between, you’ll get insightful, practical, cutting-edge conversations from the forefront of the psychedelic movement. Join us as we explore how psychedelics can be integrated into culture for the evolution of humanity.
RSS Feed Subscribe in Apple Podcasts
The Psychedelic Podcast
2024
July
June
May
April
March
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
October
September
August
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
August
July
June
May
April
March
February
January


All Episodes
Archives
Now displaying: August, 2023
Aug 28, 2023

In this Psychedelic Podcast episode, Paul F. Austin welcomes Phoebe McPherson to discuss the resurgence of kanna, a legal psychoactive plant, in the global market.

Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-210-phoebe-mcpherson

Paul and Phoebe explore kanna’s rich South African history, heart-opening qualities, and recent revival in the wellness space. Their comprehensive discussion asks questions like: How does kanna compare to MDMA? What led Phoebe to explore kanna, and how did it change her life? How can this plant help regulate the nervous system? Can you stack kanna extract with psychedelics like psilocybin and LSD? What does a kanna microdosing protocol look like?

Paul and Phoebe uncover everything you need to know about starting a kanna protocol, safe product sourcing, and ingestion tips.

Phoebe McPherson:

Phoebe McPherson is an educator, herbalist, gatherer, and the Head of Brand & Education at Fungtion, a nature-inspired wellness brand on a mission to help people reconnect to their bodies and nature through mushroom and plant formulas. Phoebe has spent years working with and learning from experts in the field about the healing aspects of nature’s gifts. While she is deeply knowledgeable about medicinal mushrooms, psychedelics, and plants, her passion lies in sharing kanna (Sceletium tortuosum) with the world, helping others find safety in their first steps to connect with nature.

Highlights:

  • Understanding kanna benefits and traditional usage.
  • Phoebe’s journey to kanna during pivotal shifts in her life.
  • Kanna vs. MDMA: How do they compare?
  • The story of kanna’s re-emergence in the world market.
  • Uncovering kanna’s clinical potential.
  • Combining kanna with other substances.
  • Exploring kanna as an adaptogen with psychedelic qualities.
  • Kanna supply and sustainability questions.
  • How to safely source and ingest kanna.
  • Kanna’s subjective benefits and personal healing stories.
  • How to connect with Phoebe.

Key Links:

Episode Sponsors:

Aug 21, 2023

In this Psychedelic Podcast episode, Paul F. Austin welcomes Jonathan Sabbagh, CEO of Journey Clinical, who shares his mission to integrate FDA-approved psychedelics within the modern therapeutic framework.

Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-209-jonathan-sabbagh/

Jonathan highlights the disjointed nature of today’s mental health system, where therapists and prescribers lack communication, hindering comprehensive assessments and referrals. He and Paul emphasize Journey Clinical’s collaborative care model, streamlining information exchange, and maximizing psychedelic-therapy access through telemedicine innovation. They explore Journey’s potential challenges of scalability, therapist training, and insurance coverage for extended sessions. And they consider the balance between state-level decriminalization, psychedelic medicalization, and decentralized access.

Join Paul and Jonathan as they imagine a new mental healthcare infrastructure that addresses the growing crisis and reinvents therapeutic care as we know it.

 

Jonathan Sabbagh:

Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to psychedelic-assisted psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC.

After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During that time, he personally experienced the transformative benefits of plant medicine and ketamine-assisted psychotherapy (KAP). Jonathan’s healing journey inspired him to begin formal clinical psychology training at the New School, with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans with depression and anxiety.

Jonathan’s personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.

Highlights:

  • How Jonathan’s mental health & finance background led him to start Journey Clinical.
  • Jonathan’s take on co-founding and running Journey Clinical with his wife.
  • The origin story of Journey Clinical and its startup challenges.
  • Exploring Journey’s collaborative care model.
  • Investigating Journey’s infrastructure solution for psychedelic-assisted therapy.
  • Journey’s vetting requirements for network therapists.
  • How the Ryan Haight Act might affect ketamine telehealth access.
  • Journey’s decentralized approach to safe and responsible ketamine telemedicine.
  • Integrating FDA-approved psychedelics into the mainstream mental health infrastructure.
  • Jonathan’s long-term vision for collaborative mental health care through Journey Clinical.

Key Links:

Episode Sponsors:

Aug 14, 2023

In this Psychedelic Podcast episode, Paul F. Austin meets meditation teacher and healer Spring Washam at the MAPS Psychedelic Science Conference to discuss Buddhism, psychedelics, and ancestral wisdom.

Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-208-spring-washam

Paul and Spring delve deep into the synergies and incompatibilities across healing modalities. They ask whether indoor practices can ever rival nature’s transformative power. They reflect on innate desires toward rooting on land and the consequences of disconnection. They ask whether the spirit of Harriet Tubman and other ancestral heroes can heal society’s conflicts. And they explore the psychedelic divide between Southern traditions and Northern adaptations.

Join Paul and Spring for a fascinating perspective on mindfulness, plant medicine, and the evolution of society.

Spring Washam:

Considered a pioneer in bringing mindfulness-based meditation to diverse communities; Spring Washam is a well-known teacher, healer, and visionary leader based in Oakland, California.

She is the author of A Fierce Heart: Finding Strength, Courage and Wisdom in Any Moment and The Spirit of Harriet Tubman: Awakening from the Underground.

Spring is one of the founding teachers at the East Bay Meditation Center, an organization that offers Buddhist teachings with attention to social action and multiculturalism. She is a member of the teachers’ council at Spirit Rock Meditation Center, offering teachings on Buddhist philosophy, Insight meditation, and loving-kindness practices. Spring is also the founder of Lotus Vine Journeys, a one-of-a-kind organization that blends indigenous healing practices with Buddhist wisdom in transformative retreats in Central America.

She has practiced and studied Buddhist philosophy in both the Theravada and Tibetan schools of Buddhism since 1999. Spring is also a shamanic practitioner, studying indigenous healing practices since 2008.

Spring’s workshops, interviews, and writing can be found in mainstream media worldwide.

Highlights:

  • How Buddhist practitioners view psychedelics.
  • Spring’s early ayahuasca journeys and revelations.
  • Spring’s lessons from Buddhist lineages.
  • Jack Kornfield’s guidance and teachings.
  • Spring’s Lotus Vine Journeys ayahuasca retreats in Costa Rica.
  • How psychedelics and Buddhism reconnect us to nature.
  • Spring’s journey from California to Georgia to start a plant-medicine community.
  • Exploring the importance of healing human disconnection from the land.
  • Spring’s insights from her book, The Spirit of Harriet Tubman: Awakening from the Underground.
  • Spring’s presentation at the MAPS Conference on Buddhism & ayahuasca.
  • Reflecting on how to bridge modern spirituality with indigenous lineages.

Key Links:

These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

Continue the conversation about this episode in Third Wave Community. Create your account for free at community.thethirdwave.co

Episode Sponsors:

Aug 7, 2023

In this episode of the Psychedelic Podcast, Paul F. Austin welcomes Christian Angermayer, a serial entrepreneur and investor in psychedelics, longevity, fintech, crypto, and future tech.

Get full show notes, links, and transcript here: https://thethirdwave.co/podcast/episode-207-christian-angermayer/

Christian is a notable figure in the field of psychedelic medicine, both respected and controversial. He has been a driving force in pushing psilocybin toward FDA-approval. But his company atai Life Science's psychedelic patents have drawn criticism from decriminalization-first advocates. Some wonder if the medical approach to psychedelics conflicts with the idea of open access and shamanic usage. Christian delves into this question, examining opposing views and exploring other dichotomies, such as whether capitalism and spirituality can coexist in the realm of psychedelics. He also considers the potential conflict between the search for psychedelic wisdom and the desire for immortality.

Christian’s conversation with Paul presents a new perspective on psychedelics, exploring nuanced topics and questioning the future of psychedelic biotech, microdosing, and longevity science.

Christian Angermayer:

Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives.

Christian’s family office and private investment firm, Apeiron Investment Group, has more than USD 2.5 billion under management and 50 people across five international locations. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Experiences, and Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns.

Christian is the world’s largest investor in psychedelics and is recognized for leading the current psychedelics renaissance. He founded atai Life Sciences, investigating the potential of psychedelic compounds including psilocybin, ketamine, DMT, and ibogaine as approved medical treatments.

Highlights:

  • Exploring psychedelics and the evolution of organized religion.
  • The parallels between ancient psychedelic traditions and modern medicalization.
  • An argument for democratizing psychedelic access through centralization.
  • Christian’s thoughts on creating a regulated framework for microdosing.
  • Optimism about longevity research and extended lifespans.
  • Overcoming deeply-rooted fears and embracing the concept of a long life.
  • Christian’s challenges and successes at COMPASS Pathways & atai Life Sciences.
  • The obstacles of commercializing psychedelic medicines in an economic downturn.
  • Investigating how psychedelics might contribute to longevity.
  • How psychedelics can help us find and live our Dharma (life’s purpose).

Key Links:

Apeiron Investment Group: https://apeiron-investments.com/

atai Life Sciences: https://atai.life/

COMPASS Pathways: https://compasspathways.com/

Episode Sponsors:

1